Omega Therapeutics reports Q3 results

seekingalpha
15 Nov 2024
  • Omega Therapeutics press release (NASDAQ:OMGA): Q3 net loss of $16.4M, compared to $22.2M for the third quarter of 2023.
  • The decrease in net loss was driven predominantly by the decrease in R&D and G&A expenses.
  • Revenue of $2.61M (vs. $831K in Q3 2023).
  • As of Sept. 30, 2024, the company had cash and cash equivalents totaling $30.4M, which is expected to fund operations into Q2 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10